An investment bank based in the US actively seeks new investment opportunities. The firm does not act as a traditional investment bank, as they participate in venture capital, investing in and working with early-stage technology and life science companies with the main goal of taking the companies to public market. The firm generally does not look at digital health. The firm has also spun out and out-licensed technologies from universities and has capabilities to help with company formation, business strategy, IP, and early IPOs. The firm utilizes their sister company to further analyze company technologies and IPs. The firm can fund from $5M-12M USD from Seed to Series A rounds with preference in US-based companies, though open to global companies.
The firm is looking at biotech, medical devices, and diagnostics companies and is technology-agnostic. The firm generally does not look at digital health. There has been strong interest in immuno-oncology, neurology, and CNS.
The firm works closely with companies and founder and will lead investment rounds. The firm typically requires taking a board or observer seat while deciding strategy, and once the company goes public, the firm will bring in a board member with expertise in the field.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment